medigraphic.com
ISSN 1561-302X (Impreso)

2023, Número 1

<< Anterior Siguiente >>

Rev cubana med 2023; 62 (1)


Proteinuria y síndrome nefrótico

López GFE, Jiménez RR, Ramírez MCE, Suarez PYM

Idioma: Español
Referencias bibliográficas: 26
Paginas: 1-11
Archivo PDF: 355.43 Kb.


RESUMEN

Introduction: Nephrotic syndrome is a pathology that affects the glomerular complex of the kidney, characterized by proteinuria greater than 3500 mg/d. According to the response to steroids, nephrotic syndrome can be classified as steroid-resistant or steroid-sensitive.
Objective: To determine the relationship between proteinuria and the variants of the nephrotic syndrome in adults.
Methods: A descriptive, retrospective, case series type study was carried out with a population of 28 patients. The data was collected and processed through Epi-Info 7.2TM software; simple frequency, statistical mean, student's t-test, and Pearson's correlation coefficient.
Results: The statistically significant difference was obtained in the antiproteinuric and non-statin group, between the mean post-treatment proteinuria of the steroid resistant nephrotic syndrome group (6202 mg/d) in comparison to steroid sensitive nephrotic syndrome (65.9 mg/d) (p value 0.0418). There is negative correlation between post-treatment proteinuria levels and post-treatment serum albumin level (r= -0.7 p value <0.00001).
Conclusions: The absence of association between initial proteinuria and steroid-sensitive and steroid-resistant variants of nephrotic syndrome was demonstrated (p value=0.8).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sinnakirouchenan Ramapriya. Nephrotic Syndrome: Practice Essentials, Pathophysiology, Etiology. 2021 [acceso 11/10/2021] Disponible en: https://emedicine.medscape.com/article/244631-overview1.

  2. Tapia C, Bashir K. Nephrotic Syndrome. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing; 2021 [acceso 11/10/2021]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK470444/2.

  3. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO. 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100(4):S1-276. DOI: https://doi.org/10.1016/j.kint.2021.05.0213.

  4. Königshausen E, Sellin L. Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome. Biomed Res Int. 2017;2017:7689254. DOI: https://doi.org/10.1155/2017/76892544.

  5. Kelepouris E, Rovin BH. Overview of heavy proteinemia and the nephrotic syndrome. UpToDate. 2019. [acceso 09/09/2021]. Disponible en: https://www.uptodate.com5.

  6. Dove E, Kowalewska J. Educational Case: Nephrotic Syndrome in Older Adult. Acad Pathol. 2020 [acceso 11/10/2021];7. DOI: https://doi.org/10.1177/23742895209445546.

  7. Halty M, Caggiani M, Cocchi V, Noria A, Giachetto G, Halty M, et al. Evolución del síndrome nefrótico idiopático del niño. Archivos de Pediatría del Uruguay. 2020;91(6):359-69. DOI: https://doi.org/10.31134/AP.91.6.47.

  8. Schijvens AM, Heine R, Wildt SN de, Schreuder MF. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatric Nephrol. 2019;34(3):389-403. DOI: https://doi.org/10.1007/s00467-018-3929-z8.

  9. Wei L, MacDonald TM, Walker BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764-70. DOI: https://doi.org/10.7326/0003-4819-141-10-200411160-000079.

  10. Hull RP, Goldsmith DJA. Nephrotic syndrome in adults. BMJ : British Medical Journal. 2008;336(7654):1185-9. DOI: https://doi.org/10.1136/bmj.39576.709711.8011.

  11. Fernández Collahuazo CN. Prevalencia y factores asociados a síndrome nefrótico en adultos atendidos en el hospital Vicente Corral Moscoso. Diciembre 2014 a diciembre 2016. 2017. Disponible en: https://dspace.ucacue.edu.ec/bitstream/ucacue/7061/1/9BT2017-MTI07.pdf12.

  12. Hernández-Ordóñez SO. Síndrome nefrótico. Residente. 2008 [acceso 09/09/2021];3(3):90-6. Disponible en: https://www.medigraphic.com13.

  13. López-Gómez J, Rivera F. Registro de glomerulonefritis de la Sociedad Española de Nefrología en 2019: pasado, presente y nuevos retos. Nefrología. 2020 [acceso 25/09/2021]; 40(4). Disponible en: https://www.revistanefrologia.com/es-registro-glomerulonefritis-sociedad-espanola-nefrologia-articulo-S021169952030069214.

  14. Jellouli M, Brika M, Abidi K, Ferjani M, Naija O, Hammi Y, et al. Nephrotic syndrome in children: risk factors for steroid dependence. Tunis Med. 2016 [acceso 16/03/2019];94(7):401-5. Disponible en: http://pesquisa.bvsalud.org/portal/resource/es/mdl-2805122815.

  15. Chang-Chien C, Chuang G-T, Tsai I-J, Chiang B-L, Yang Y-H. A large retrospective review of persistent proteinuria in children. J Formos Med Assoc. 2018;117(8):711-9. DOI: http://dx.doi.org/10.1016/j.jfma.2017.09.00416.

  16. Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, et al. Complete Remission in the Nephrotic Syndrome Study Network. Clin J Am Soc Nephrol. 2016;11(1):81-9. DOI: http://dx.doi.org/10.2215/CJN.0256031517.

  17. Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS, Bodria M, Ozaltin F, Emma F, et al. Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. J Am Soc Nephrol. 2017;28(10):3055-65. DOI: http://dx.doi.org/10.1681/ASN.201610112118.

  18. Sánchez-García C, Bailón-Ortega AA, Zaltzman-Girshevich S. Tratamiento con estatinas en pacientes pediátricos con síndrome nefrótico resistente a esteroides. Reporte de dos casos. Acta Pediatr Mex. 2017 [acceso 09/09/2021];38(1):26-32. Disponible en: https://www.medigraphic.com19.

  19. Santín S, Bullich G, Tazón-Vega B, García-Maset R, Giménez I, Silva I, et al. Clinical Utility of Genetic Testing in Children and Adults with Steroid-Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol. 2011;6(5):1139-48. DOI: http://dx.doi.org/10.2215/CJN.0526061020.

  20. Kim S, Uhm J-Y. Individual and Environmental Factors Associated with Proteinuria in Korean Children: A Multilevel Analysis. International Journal of Environmental Research and Public Health. 2019 [acceso 11/10/2021];16(18). Disponible en: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6766052/21.

  21. Gupta K, Iskandar SS, Daeihagh P, Ratliff HL, Bleyer AJ. Distribution of pathologic findings in individuals with Nephrotic proteinuria according to serum albumin. Nephrol Dial Transplant. 2008;23(5):1595-9. DOI: http://dx.doi.org/10.1093/ndt/gfm83322.

  22. Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L. Lipid-lowering agents for Nephrotic syndrome. Cochrane Database Syst Rev. 2013;10(12):CD005425. DOI: http://dx.doi.org/10.1002/1465185823. . CD005425.pub2. [ Links ]

  23. Floege J. Introduction to glomerular disease: clinical presentations. Johnson RJ, Feehally J, Floege J, eds. In: Comprehensive Clinical Nephrology. 5th ed. Philadelphia, Elsevier Saunders; 2015. [ Links ]

  24. Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with Nephrotic syndrome. Am J Med. 2008;121(3):226-30. DOI: http://dx.doi.org/10.1016/j.amjmed.2007.08.04225.

  25. Kodner C. Nephrotic Syndrome in Adults: diagnosis and management of. Am Fam Physician. 2009 [acceso 11/10/2021];80(10):1129-34. Disponible en: https://pumed.ncbi.nlm.nih.gov26.

  26. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57-70. DOI: http://dx.doi.org/10.1038/nrneph.2017.15527.




2020     |     www.medigraphic.com